CRISPR-Cas9 In Vivo Gene Editing for Transthyretin Amyloidosis

Share:

Neurology Minute

Miscellaneous


Dr. Alberto Espay talks with Prof. Julian Gillmore about CRISPR-Cas9 in vivo gene editing for transthyretin amyloidosis. Show references: https://www.nejm.org/doi/full/10.1056/NEJMoa2107454